news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

in the current psoriasis treatment practice, deveba (calcipotriol betamethasone) has been proven to be an effective supplement for patients who are treated solely with biological agents such as tuozi, tenoya, cosentyx and other drugs. . although these biological agents have achieved remarkable results in relieving symptoms and delaying disease progression, they still have limitations, such as slow onset of action, residual skin lesions, and drug resistance issues.

slow onset of effectthis is a common problem faced by patients when treated with biologics. biological agents such as tenoya and tuozi require at least 4-10 weeks (data source: j drugs dermatol (journal of dermatology drugs) march 2019) to take effect. during this period, patients may have to continue to suffer from symptoms such as itching, redness, and swelling.

also,residual skin lesionsalso a frequently asked question. even after treatment with biological agents, only an average of 28% of patients can achieve the removal of all skin lesions, and more than 55% of patients will have at least 10% of residual skin lesions (data source: jama dermatol (journal of the american academy of dermatology) 2020 march of the year). residual skin lesions not only affect the patient's appearance, but may also have a negative impact on their self-confidence and social life.

at last,failure resistancethe problem cannot be ignored. for patients who have long-term use of biologics such as dermatol ther or dermatol ther, the time to relapse shortens with the increase in the number of previous treatments; among patients who stop taking biologics for the first time, half relapse within 10 months (data source: dermatol ther (dermatology treatment) magazine) september 2021). this may force patients to require higher doses or more frequent injections to maintain treatment effects, increasing the economic burden and risk of side effects.

as an effective topical drug, deflex (calcotriol betamethasone) can effectively solve these problems when used in combination with tenoya, tuozi and cosentyx. defubao (calcipotriol betamethasone) contains calcipotriol and betamethasone, which have anti-inflammatory, immunomodulatory and skin repair effects. its external form can quickly relieve skin itching and redness, provide patients with immediate symptom improvement, and accelerate skin damage repair.

the advantage of combined use of deveba (calcipotriol betamethasone) is that it can not only improve the overall efficacy of biological agents, shorten treatment time, and reduce the intensity of inflammatory reactions, but also significantly reduce residual skin lesions, and even achieve full recovery.

the most important thing is that after combined use with deveba (calcipotriol betamethasone), patients can reduce the frequency and dosage of biological agents such as tuozi, tenoa and cosentyx. betamethasone triol) can prolong the effective time of these drugs, reduce the risk of drug resistance in patients, reduce the financial burden on patients, and enable more patients to adhere to treatment.

therefore, in chapter 4 of the chinese psoriasis diagnosis and treatment guidelines (2023 edition), it is clearly stated that the combined use of biological agents and calcipotriol betamethasone can improve the condition faster in the initial stage, and can help resolve some skin lesions in the maintenance stage. refractory or recurring conditions, and can shorten response time to biologic agents.

therefore, we recommend that patients who are using biologics such as tuozi, tenoya and cosentyx alone to treat psoriasis consider adding deveba (calcipotriol betamethasone) to their daily treatment according to their own condition. get better treatment results.